Bridgefront Capital LLC Purchases 7,037 Shares of GSK plc (NYSE:GSK)

Bridgefront Capital LLC lifted its position in GSK plc (NYSE:GSK - Free Report) by 73.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,665 shares of the pharmaceutical company's stock after acquiring an additional 7,037 shares during the period. Bridgefront Capital LLC's holdings in GSK were worth $564,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. World Investment Advisors LLC purchased a new stake in shares of GSK in the 3rd quarter worth approximately $421,000. Franklin Resources Inc. increased its stake in GSK by 8.6% during the 3rd quarter. Franklin Resources Inc. now owns 235,348 shares of the pharmaceutical company's stock valued at $9,052,000 after purchasing an additional 18,539 shares in the last quarter. Boltwood Capital Management lifted its stake in shares of GSK by 9.9% in the fourth quarter. Boltwood Capital Management now owns 12,453 shares of the pharmaceutical company's stock worth $421,000 after buying an additional 1,120 shares in the last quarter. Bard Financial Services Inc. grew its holdings in shares of GSK by 38.4% during the fourth quarter. Bard Financial Services Inc. now owns 79,095 shares of the pharmaceutical company's stock valued at $2,675,000 after buying an additional 21,950 shares during the last quarter. Finally, Range Financial Group LLC bought a new stake in shares of GSK during the fourth quarter valued at approximately $287,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. BNP Paribas began coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Hsbc Global Res upgraded GSK to a "strong sell" rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.58.

GSK Price Performance

NYSE:GSK traded down $0.24 during trading hours on Friday, hitting $36.63. 3,511,468 shares of the stock traded hands, compared to its average volume of 4,786,523. The stock has a 50 day moving average price of $37.65 and a 200 day moving average price of $35.99. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company has a market cap of $75.58 billion, a price-to-earnings ratio of 23.04, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter in the prior year, the firm posted $0.43 EPS. GSK's quarterly revenue was up 2.1% compared to the same quarter last year. Sell-side analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. This represents a $1.69 annualized dividend and a yield of 4.60%. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio is presently 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.